# Bibliography

References

[Bauer2009] | Beal, S., Sheiner, L.B., Boeckmann, A., & Bauer, R.J. NONMEM User’s Guides. (1989-2009), Icon Development Solutions, Ellicott City, MD, USA, 2009.

[Cheung2015] | Amy Cheung, Predictive QT project, DDMODEL 0000093, 2015, (repository.ddmore.eu/model/DDMODEL00000093).

[Christensen1980] | Finn Norring Christensen, Flemming Yssing Hansen and Helle Bechgaard Physical interpretation of parameters in the Rosin-Rammler-Sperling-Weibull distribution for drug release from controlled release dosage forms Journal of Pharmacy and Pharmacology, Volume 32, Issue 1, September 1980, pp 580-582

[DennisSchnabel1987] | J. E. Dennis, Jnr. and R. B. Schnabel Numerical Methods for Unconstrained Optimization and Nonlinear Equations Society for Industrial and Applied Mathematics ISBN-10: 0898713641

[Germovsek2017] | Eva Germovsek, Population PK model for gentamicin, DDMODEL 0000238, 2017, (repository.ddmore.eu/model/DDMODEL00000238).

[Harling2015] | Kajsa Harling Population PK of gentamicin in cancer patients with time-varying covariates, DDMODEL 0000061, 2015, (repository.ddmore.eu/model/DDMODEL00000061).

[Holford1996] | N. H. Holford, A size standard for pharmacokinetics. Clin Pharmacokinet. 1996 May; 30(5):329-32.

[KarlssonSheiner1993] | Karlsson MO and Sheiner LB The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 Dec; 21(6):735-50.

[Lindstrom1990] | L Lindstrom, M & Bates, Mark. (1990). Nonlinear Mixed Effects Models for Repeated Measures Data. Biometrics. 46. 673-87. 10.2307/2532087.

[Millar2011] | Russell B. Millar Maximum Likelihood Estimation and Inference - With Examples in R, SAS, and ADMB John Wiley & Sons, 2011

[MouldUpton2012] | D. R. Mould and R. N. Upton Basic Concepts in population Modeling, Simulation, and Model-Based drug development CPT Pharmacometrics Syst Pharmacol. 2012 Sep; 1(9): e6.

[MouldUpton2013] | D. R. Mould and R. N. Upton Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17; 2: e38.

[NocedalWright2006] | J. Nocedal and S. Wright Numerical Optimization Springer ISBN-10: 0387303030

[Piotrovskii1987] | Vladimir K. Piotrovskii The use of Weibull distribution to describe thein vivo absorption kinetics Journal of Pharmacokinetics and Biopharmaceutics, Volume 15, Issue 6, December 1987, pp 681–686

[Radhakrishnan1994] | Radhakrishnan, Krishnan & C. Hindmarsh, Alan. (1994). Description and Use of LSODE, the Livermore Solver for Ordinary Differential Equations.

[RowlandTozer2012] | M. Rowland and T. N. Tozer Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications Lippincott Williams & Wilkins, 2012

[Sheiner1980] | Sheiner L.B., Beal S.L. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm 86553–571.1980

[UptonMould2013] | R. N. Upton and D. R. Mould Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods CPT Pharmacometrics Syst Pharmacol. 2014 Jan; 3(1): e88.

[Wang2007] | Wang, Yaning. (2007). Derivation of various NONMEM estimation methods. Journal of pharmacokinetics and pharmacodynamics. 35. 249. 10.1007/s10928-008-9083-7.